Navigation Links
CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis
Date:5/31/2011

SEOUL, South Korea, May 31, 2011 /PRNewswire/ -- CrystalGenomics, Inc. (Seoul, Korea) and CG Pharmaceuticals, Inc. (Emeryville, California), a biopharmaceutical company with 3 clinical stage candidates, has announced that the first patient has been enrolled for a Phase 2b clinical study of CG100649, CrystalGenomics' clinical stage novel NSAID candidate, in patients with knee or hip osteoarthritis (OA).

CG100649 is a first-in-class NSAID drug candidate that is a dual inhibitor of COX-2 and carbonic anhydrase (CA). CG100649's interaction with carbonic anhydrase in red blood cells provides it with a novel "tissue-specific" transport mechanism that is designed to deliver sustained levels of drug to inflamed tissues, while maintaining low systemic exposure. Its unique dual COX-2 and CA binding properties are designed to provide potentially superior safety to cardiovascular, renal, and gastrointestinal tissues compared to traditional NSAIDs or COX-2 inhibitor drugs.

An earlier placebo-controlled Phase 2a efficacy study in hip and knee in 248 OA patients in Europe showed that a 1.2 mg daily dose provided a highly significant efficacy profile vs. the three major OA symptoms of pain, stiffness, and physical disability.  Although this was not an active-comparator trial, the efficacy profile of CG100649 appeared to be at least as favorable as other COX-2 drugs. This prompted CrystalGenomics to conduct a supra-threshold Phase 1 Multiple Ascending Dose (MAD) study in healthy subjects last year that showed that higher doses of CG100649 (2, 4, or 8 mg per day) are likely to provide even higher levels of efficacy while maintaining CG100649's favorable safety profile.

The current Phase 2b study is a double-blind, randomized, multicenter, non-inferiority, repeat dose study of CG100649 versus celecoxib (Celebrex®) in OA patients. This is the first time that the OA efficacy of CG100649 is being tested directly against celecoxib in the same clin
'/>"/>

SOURCE CrystalGenomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Metabolex Initiates Phase 2 Trial of Arhalofenate
2. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
3. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
4. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
5. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
6. Stephens Initiates Coverage on Vermillion
7. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
8. American Regent Initiates Voluntary Nationwide Recall of Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Single Dose Vials; 5 mL and 30 mL Multiple Dose Vials
9. CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis
10. Max Neeman International Initiates Advisory Committee to Advance and Improve the Conduct of Complex Neurological Trials in India
11. Aperion Biologics Initiates Clinical Trial of Z-Lig™ Device for Anterior Cruciate Ligament Reconstruction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015   Hospira, Inc. ... biosimilars, today announced that its partner, Celltrion – a global ... the National Health Surveillance Agency in Brazil ... monoclonal antibody approved for use in Brazil ... Hospira also markets and sells biosimilar infliximab in 26 ...
(Date:6/2/2015)... GERMANTOWN, Md. , June 2, 2015 /PRNewswire/ ... a leader in synthetic biology, announced today the ... as Senior Vice President, Consumer Sector.  Mr. Jarry ... biologically-based solutions in products and applications for consumer ... Intrexon over 30 years of experience in leading ...
(Date:6/2/2015)... Mass. , June 2, 2015  Alere ... in rapid diagnostics, joined the White House Antibiotic ... of commitments to support and advance the President,s ... Company,s commitments include a number of measurable goals ... when achieved, will help healthcare providers protect their ...
(Date:6/2/2015)... German-based Moenninghoff has designated the R.M. ... the Moenninghoff product line . , ... announce that the R.M. Hoffman Company will be representing ... in 1916, this is a strategically important step. ... of professional distributor we need to successfully grow our ...
Breaking Biology Technology:ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5Intrexon Announces New Sector Leader 2Intrexon Announces New Sector Leader 3Alere Announces Broad Initiatives to Help Combat Antibiotic Resistance during White House Antibiotic Stewardship Forum 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3
... ... , ... Waterville, ME (Vocus) April 15, 2010 -- Cerealus Holdings, in collaboration with the ... Next Generation Strength + Retention System.” Originally patented by DuPont and later developed ...
... ... turning the corner on jobs, with the worst behind us. With only 308 job cuts announced ... a steady unemployment rate for two years running, they may just be correct. , ... (Vocus) April 15, 2010 -- If the absence of ...
... ... ... when paying taxes is on every American’s mind, Cole-Parmer makes the process painless—for online ... checking out—adding shipping costs and taxes—now takes mere seconds to complete. Customers simply type ...
Cached Biology Technology:Cerealus Announces Licensing Agreement for Bio-Based Ceregel™, A Next Generation Strength and Retention System 2The MedZilla Report for April 2010 - Pharma Layoffs Drop Below 400 in March; Health Care Adds Another 27,000 Jobs 2The MedZilla Report for April 2010 - Pharma Layoffs Drop Below 400 in March; Health Care Adds Another 27,000 Jobs 3Cole-Parmer Announces Automatic Tax Calculation for Online Purchases 2
(Date:5/21/2015)... The Sync Project™ , a global ... today announced a collaborative partnership with Berklee,s Institute ... on collaboration on original research, joint course development and ... collaboration, The Sync Project and BerkleeICE are exploring the ... the 2015-2016 academic year.  The course ...
(Date:5/19/2015)...  Technology is rapidly advancing, outpacing enterprises, ability to ... Passwords and their management are soon to be rendered ... such as those developed by the FIDO Alliance™. With ... for BYOD, COPE, IoT, and mobile payments, the interconnected ... In response to the call for seamless, ...
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... SACRAMENTO, Calif. -- The University of California, Davis, and ... have signed a historic agreement that will change the ... states, and foster critical breakthroughs in the areas of ... new partnership will establish a state-of-the-art BGI sequencing facility ...
... In an experiment on rats, European researchers have proved ... cause to the stomach mucous membrane. Published in the ... to improving the treatment of stomach ulcers. A ... the protecting effect that strawberries have in a mammal ...
... era of environmental consciousness, many buildings are being outfitted to ... literally. Elizabeth Demaray, an associate professor of fine arts, ... skyscrapers to counteract the lack of native vegetation found in ... part of New York,s Art in Odd Places Festival from ...
Cached Biology News:UC Davis and BGI announce partnership to establish state-of-the-art genome center in Sacramento 2UC Davis and BGI announce partnership to establish state-of-the-art genome center in Sacramento 3Strawberries protect the stomach from alcohol 2Rutgers professor uses lichen to help cities go green 2Rutgers professor uses lichen to help cities go green 3
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum....
... contains a unique β-agarose digesting enzyme developed ... intact DNA and RNA from low melting ... TAE, TBE, MOPS, or phosphate buffers. The ... TAE, TBE, MOPS, and phosphate electrophoresis buffers ...
... Terminal deoxynucleotidyl transferase (TdT) is an intracellular ... cortical thymocytes and minor subpopulation of bone ... and increased numbers of TdT cells are ... leukaemias and lymphomas. Presence of TdT thus ...
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
Biology Products: